Objectives: To describe: the pattern of anti-ENA positive tests; frequency of repeated requests; stability and repeatability of anti-Jo-1 tests; clinical characteristics of anti-Jo-1 +ves compared with controls; and diagnostic value of anti-Jo-1 for ILD. Methods: All anti-ENA test requests, from any hospital department, between Jan 2013 and Dec 2014 were identified. Serum samples are screened for ENA (Quanta Lite ® ENA profile, Inova Diagnostics) and positive samples have specific ENA antibodies levels quantified. Data from anti-Jo-1 positive patients and controls was extracted from electronic records allowing a minimum of 12 months after first test. Results:
. Of patients with the highest anti-Jo1 titres (≥40 AU/mL, 10/40 patients, 25%): 3 had ILD, 1 myositis and 2 had a malignancy (disseminated melanoma and CML). Bland-Altman plots show that anti-Jo-1 values remained stable when patients were re-tested at another time but re-testing available stored samples from +ve patients showed important variation ( Figure) .
Conclusions: Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD. When tested repeatedly levels remain stable over many months. Repeated testing for anti-ENA is common and potentially unnecessary. Controls over repeated requests could yield cost savings. Background: In rheumatoid arthritis (RA), patients in low activity disease or clinical remission measured by disease activity indexs can present subclinical activity by ultrasound study. The ultrasonographic inflammation in examination of joints is an important predictive value of structural damage. Objectives: The aim of our study was to describe subclinical ultrasonographics activity in patients with RA in low disease activity or clinical remission, with optimized biological therapy and non biological treatment. Methods: Transversal and longitudinal study describing the ultrasonographic changes in gray scale and doppler in parallel with blind clinical evaluation. We included patients with RA according to ACR/EULAR classification criteria in low activity disease or remission measured by DAS28, under optimized biological therapy at least for 6 months and non biological treatment. They were sent by their usual clinician, making a random selection. They were evaluated in the same day by a rheumatologist and blind sonographer. VAS, VGP, VGM, HAQ, tender joints count, swollen joint count, CDAI, SDAI and DAS28 were evaluated. Regarding the ultrasound, were evaluated synovitis and doppler in 12 joints (wrists, second to fifth MCF and fifth bilateral MTF). The comparison between clinical examination and ultrasonography test was performed by the kappa index, with satisfactory value of >0,6. Results: A total of 69 patients were included, 35 with optimized biological therapy and 34 non biological treatment. The median optimization time was 12 months. The baseline characteristics only offered stadistical significance in swollen joint count and average time of disease (table 1). The concordance study between clinical joint exploration and ultrasonographic examination showed a higher kappa index in patients with optimized biological therapy: 0,52 in gray scale and 0,40 in doppler. In patients without biological therapy showed an index kappa =0.17 by the gray scale test, and kappa index =0.26 by doppler. 
